Charles River Laboratories (CRL) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY25 EPS Guidance
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Price: $181.56 -1.86%
EPS Growth %: -12.5%
Financial Fact:
Net income attributable to common shareowners: 37.74M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -12.5%
Financial Fact:
Net income attributable to common shareowners: 37.74M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $3.12, $0.62 better than the analyst estimate of $2.50. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $984.86 million.
GUIDANCE:
Charles River Laboratories sees FY2025 EPS of $9.90-$10.10, versus the consensus of $9.65.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
- JPMorgan Starts Central Depository Services India Ltd (CDSL:IN) at Underweight
- Barclays Downgrades Telenor ASA (TEL:NO) (TELNY) to Underweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
